Drugs / 68Ga-PSMA-33
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06054789 | Oct 2022 → Oct 2023 | prostate cancer | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-PSMA-33 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06054789 ↗ |
| Modality | Diagnostic / imaging agent | “a PET radiopharmaceutical selective for Prostate-Specific Membrane Antigen” NCT06054789 ↗ |
| Route | Intravenous | “All patients were intravenously injected with 68Ga-PSMA-33” NCT06054789 ↗ |